logo-loader

Paradigm Biopharmaceuticals in a trading halt as news pending

Published: 11:30 15 Jun 2017 AEST

ASX-Exchange-Centre-Bridge-St-757-highres
Paradigm is a biopharmaceutical company

Paradigm Biopharmaceuticals (ASX:PAR) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Paradigm requested the halt pending the company reviewing the status of its current clinical trial in allergic rhinitis.

The halt will remain in place until the opening of trade on Monday 19th June 2017, or earlier if an announcement is made to the market.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 46 minutes ago